ArticleTurkish journal of biology = Turk biyoloji dergisi2025
Differential modulation of cisplatin efficacy by montelukast sodium and desloratadine in lung cancer.
Article in Turkish journal of biology = Turk biyoloji dergisi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objective: Despite advances in treatment, achieving effective and durable responses with chemotherapy remains a significant challenge in lung cancer management. This study investigates the effects of montelukast sodium (MLS) and desloratadine (DES), alone and in combination with cisplatin (CIS), on cell viability, apoptosis, cell cycle distribution, and antioxidant gene expression in A549 and DMS114 lung cancer cell lines. Materials and methods: Cells were treated with CIS, MLS, DES, and their combinations for 24-72 h. Cell viability was assessed via MTS assay; apoptosis and cell cycle progression were analyzed by flow cytometry. The expression of antioxidant-related genes ( Results: MLS and DES reduced cell viability individually in both cell lines in a dose- and time-dependent manner. The combination of CIS and MLS showed near-synergistic effects in A549 cells. The combination significantly enhanced apoptosis, particularly in DMS114 cells. In contrast, CIS combined with DES showed antagonistic interactions in both lines, with no significant increase in apoptosis compared to CIS alone. MLS combined with CIS also enhanced G0/G1 phase arrest, while the combination of DES and CIS had no additive effect on the cell cycle. DES alone or with CIS significantly upregulated Conclusion: MLS enhances CIS-induced cytotoxicity and apoptosis in lung cancer cells and modulates redox gene expression, potentially improving therapeutic efficacy. In contrast, DES may attenuate CIS activity through antioxidant gene upregulation. These findings support the potential of MLS as an effective adjuvant in CIS-based lung cancer treatment. However, the antagonistic effect observed with DES highlights the importance of careful evaluation of candidates for drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.